Editorial
Accepted on 23 Dec 2024
Editorial: Model Organisms in Respiratory Pharmacology
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1540222
Type at least 3 characters
588 articles
Articles
Original Research
Accepted on 20 Dec 2024
Unphysiological lung strain promotes ventilation-induced lung injury via activation of the PECAM-1/Src/STAT3 signaling pathway Authors
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1469783
Original Research
Accepted on 19 Dec 2024
High-risk adverse events in two types of single inhaler triple-therapy: a pharmacovigilance study based on the FAERS database
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1460407
Original Research
Accepted on 30 Nov 2024
Mitigating Inflammation and Fibrosis: The Therapeutic Potential of Quercetin Liposomes in COPD
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1503283
- 195 views
Original Research
Accepted on 16 Dec 2024
Uvaol attenuates TGF-β1-induced epithelial-mesenchymal transition in human alveolar epithelial cells by modulating expression and membrane localization of β-catenin
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1504556
Original Research
Accepted on 16 Dec 2024
CD146 promotes resistance of NSCLC brain metastases to pemetrexed via the NF-ÎşB signaling pathway
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1502165
Review
Accepted on 11 Dec 2024
Mitochondrial quality control: a pathophysiological mechanism and potential therapeutic target for chronic obstructive pulmonary disease
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1474310
Original Research
Accepted on 03 Dec 2024
A Novel Non-invasive Murine Model for Rapidly Testing Drug Activity via Inhalation Administration against Mycobacterium tuberculosis
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1400436
Case Report
Published on 22 Nov 2024
Rare cancer with primary pleural epithelioid hemangioendothelioma diagnosed by thoracoscopic biopsy achieving disease control after 16Â months: case report and literature review
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1482154
- 321 views
Review
Published on 13 Nov 2024
Pyroptosis in asthma: inflammatory phenotypes, immune and non-immune cells, and novel treatment approaches
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1452845
- 633 views
Original Research
Accepted on 11 Nov 2024
α-Bisabolol alleviates diesel exhaust particles-induced lung injury and mitochondrial dysfunction by regulating inflammatory, oxidative stress and apoptotic biomarkers through the c-Jun N-terminal kinase signalling pathway
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1485101
Review
Published on 08 Nov 2024
Bacteria and fungi of the lung: allies or enemies?
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1497173
- 390 views
Case Report
Published on 07 Nov 2024
Characteristics of voriconazole-induced visual disturbances and hallucinations: case reports and literature review
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1420046
- 479 views
Original Research
Published on 28 Oct 2024
Therapeutic targets for lung cancer: genome-wide Mendelian randomization and colocalization analyses
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1441233
- 936 views
Correction
Published on 25 Oct 2024
Corrigendum: CHF6297: a novel potent and selective p38 MAPK inhibitor with robust anti-inflammatory activity and suitable for inhaled pulmonary administration as dry powder
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1497520
- 263 views
Review
Published on 09 Oct 2024
Emerging small-molecule antiviral agents in long COVID prevention
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1457672
- 1,295 views